Abstract
Metabolic syndrome is defined as a set of health risk factors that are associated with an increased chance of cardiovascular diseases and type 2 diabetes. These include abdominal obesity, hyperglycemia, impaired glucose tolerance, dyslipidemia, and hypertension. Interventions in metabolic syndrome include lifestyle interventions such as a healthy diet using functional foods together with increased physical activity to induce weight loss as the first aim of treatment. Nutraceuticals such as tocotrienols and tocopherols as members of the vitamin E family may be more targeted interventions. This review evaluates the effects of tocotrienols on the risk factors of metabolic syndrome using data from human, animal and in vitro studies. Tocotrienols improved lipid profiles and reduced atherosclerotic lesions, decreased blood glucose and glycated hemoglobin concentrations, normalized blood pressure, and inhibited adipogenesis. The differences in responses between tocopherols and tocotrienols in preventing obesity, diabetes, hypertension, artherosclerosis, ischemia, and inflammation suggest that different receptors or signaling mechanisms may be involved.
Keywords: Metabolic syndrome, tocotrienols, tocopherols, diabetes, hypertension, atherosclerosis, adipogenesis, artherosclarosis, chylomicrons, hepatocytes
Current Pharmaceutical Design
Title: Nutrapharmacology of Tocotrienols for Metabolic Syndrome
Volume: 17 Issue: 21
Author(s): Wong Weng-Yew and Lindsay Brown
Affiliation:
Keywords: Metabolic syndrome, tocotrienols, tocopherols, diabetes, hypertension, atherosclerosis, adipogenesis, artherosclarosis, chylomicrons, hepatocytes
Abstract: Metabolic syndrome is defined as a set of health risk factors that are associated with an increased chance of cardiovascular diseases and type 2 diabetes. These include abdominal obesity, hyperglycemia, impaired glucose tolerance, dyslipidemia, and hypertension. Interventions in metabolic syndrome include lifestyle interventions such as a healthy diet using functional foods together with increased physical activity to induce weight loss as the first aim of treatment. Nutraceuticals such as tocotrienols and tocopherols as members of the vitamin E family may be more targeted interventions. This review evaluates the effects of tocotrienols on the risk factors of metabolic syndrome using data from human, animal and in vitro studies. Tocotrienols improved lipid profiles and reduced atherosclerotic lesions, decreased blood glucose and glycated hemoglobin concentrations, normalized blood pressure, and inhibited adipogenesis. The differences in responses between tocopherols and tocotrienols in preventing obesity, diabetes, hypertension, artherosclerosis, ischemia, and inflammation suggest that different receptors or signaling mechanisms may be involved.
Export Options
About this article
Cite this article as:
Weng-Yew Wong and Brown Lindsay, Nutrapharmacology of Tocotrienols for Metabolic Syndrome, Current Pharmaceutical Design 2011; 17(21) . https://dx.doi.org/10.2174/138161211796957445
DOI https://dx.doi.org/10.2174/138161211796957445 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Understanding the Mechanism and Prevention of Arterial Occlusive Thrombus Formation by Anti-Platelet Agents
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Current Vascular Pharmacology Antisense Oligonucleotides as a Powerful Molecular Strategy for Gene Therapy in Cardiovascular Diseases
Current Pharmaceutical Design Aquaporins in Sensory and Pain Transmission
Current Neuropharmacology Benzopyran Derivatives as Cardio-selective ATP-sensitive Potassium Channel Openers: A Review
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: Advances in Particle Engineering and Powder Technology for Pharmaceutical Solid Dosage Forms)
Current Pharmaceutical Design New Vectors and Strategies for Cardiovascular Gene Therapy
Current Gene Therapy Visit-to-visit Blood Pressure Variability and Arterial Stiffness: Which Came First: The Chicken or the Egg?
Current Pharmaceutical Design Insulin Resistance in the Early Stages of Renal Failure: Implications for Cardiovascular Risk
Current Diabetes Reviews Sorafenib Decreases Extrahepatic Collaterals in Hepatocellular Carcinoma: Implication of the Synergistic Effect of Sorafenib and Transcatheter Chemoembolization
Current Medical Imaging Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews Acute and Long-Term Effects of Cannabis Use: A Review
Current Pharmaceutical Design Dose-related Effects of Resveratrol in Different Models of Pulmonary Arterial Hypertension: A Systematic Review
Current Cardiology Reviews Adiposity and Alzheimers Disease
Current Alzheimer Research Platelet Microparticles Induce Angiogenesis and Neurogenesis after Cerebral Ischemia
Current Neurovascular Research Stroke as a Consequence of Sleep Apnea: Epidemiology, Pathophysiology and Treatment Strategies
Current Respiratory Medicine Reviews The Role of Diabetes in Molecular Pathogenesis of Cancer
Current Signal Transduction Therapy The Role of Nano-ophthalmology in Treating Dry Eye Disease
Pharmaceutical Nanotechnology Association of Genetic Polymorphisms of CYP2C9 and VKORC1 with Bleeding Following Warfarin: A Case-Control Study
Current Clinical Pharmacology The Role of Sympathetic Nervous System in the Progression of Chronic Kidney Disease in the Era of Catheter Based Sympathetic Renal Denervation
Current Clinical Pharmacology